AdvaMed CEO Scott Whitaker says the industry group was lobbying the Biden administration during its transition period more than a year ago to invest in COVID-19 tests, long before the current national shortage of the diagnostics. He says there are lessons learned over the past two years that can be used to make sure the country is prepared for the pandemic’s next wave.
“We were talking to them during the transition about what would be required to avoid the shortage and to avoid...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?